JNJ vs PFE
Johnson & Johnson vs Pfizer stock: which is the better buy?
Tickerday reads Johnson & Johnson as a Hold at 59 and Pfizer as a Hold at 50. Today, Johnson & Johnson is the stronger call.
Try it on the stock you're thinking about. First one free, no account needed.
JNJ
Johnson & Johnson
Hold59/100
Partly cloudy, with 60% confidence
A year from now: $265 (+3.9%)
PFE
Pfizer
Hold50/100
Partly cloudy, with 60% confidence
A year from now: $27 (+7.1%)
Under the hood
Factor by factor
The six things Tickerday weighs, each scored 0 to 100. The higher of each pair is in its call's color.
Johnson & Johnson
Pfizer
Overall score
Valuation
Growth
Profitability
Momentum
Financial Health
Sentiment
Where they're headed
Price targets
Each target is measured from the price on the day its stock was read.
Johnson & Johnson
Pfizer
Price when read
JNJ$254.97 · Oct 21, 2026
PFE$25.21 · Jun 20, 2026
Next week
JNJ$254 (−0.4%)
PFE$24.50 (−2.8%)
Next month
JNJ$258 (+1.2%)
PFE$25 (−0.8%)
Next year
JNJ$265 (+3.9%)
PFE$27 (+7.1%)
The numbers
Key numbers
Johnson & Johnson
Pfizer
Market Cap
JNJ$625.0B
PFE$143.7B
P / E Ratio
JNJ38.9
PFE19.2
Rev. Growth
JNJ+7.8%
PFE+1.4%
Net Margin
JNJ+16.2%
PFE+11.8%
Debt / Equity
JNJ0.58
PFE0.72
Dividend Yield
JNJ2.0%
PFE6.8%
Beta
JNJ0.20
PFE0.29
52-Wk Range
JNJ$185 – $281
PFE$23 – $29
The argument
The case for and against
Every call has a case against it. Here are both sides, for each stock.
Johnson & Johnson JNJ
The case for
- Highly profitable business with strong gross margins (67.7%) and net margins (16.2%).
- Solid financial footing, with a low debt-to-equity ratio of 0.58.
The case against
- Stock appears expensive with a Price-to-Earnings (P/E) ratio of 38.9.
- Recent stock price momentum has faded after a strong year-long run.
Pfizer PFE
The case for
- Strong profitability with excellent gross margins and healthy net margins.
- A very attractive dividend yield of 6.8% provides significant income for investors.
The case against
- Revenue growth is currently very low, indicating challenges in expanding its top line.
- The stock has experienced negative momentum recently, particularly in the short term.
Tickerday's reads are educational analysis, the same for everyone, not financial advice. Johnson & Johnson was read on Oct 21, 2026 and Pfizer on Jun 20, 2026; each one's page has the full forecast.
Comparing stocks takes hours.
Tickerday takes seconds.
Now try yours
What about your stocks?
You just compared Johnson & Johnson and Pfizer. Type a company you own and get its call, and the why, in seconds. First one free, no account needed.
The receipts
Called it. Then it happened.
Real calls from the Tickerday engine, each one graded against the real price a month later.
Every call is graded
One month after the call, at the closing price.
Palantir Technologies Inc
+52.3%
✓Called it
We said Buy at $122.33 on Jul 30. A month later the price was $186.29.
Graded Aug 28 at the closing price
One blind call costs more
than a year of Tickerday.
Pricing
Start free, right here
Your first analysis is free, no account needed. Tickerday+ takes it from there.
Tickerday+
Pro
Built for fast clarity.
- Clear buy / hold / sell-style insights
- Key risks and opportunities
- Focused market analysis
- 40 priority credits every month
Billed monthly · ≈ $0.30/day
Tickerday+
Most popularPremium
The full why, explained.
- Expanded analysis & learning depth
- Interactive explanations & breakdowns
- Tap to understand key metrics & terms
- 100 priority credits every month
Billed yearly · ≈ $14.08/mo≈ $0.46/day
Cancel anytime.
FAQ
Good questions
Coming soon to the App Store
The market never sleeps.
That doesn't mean you shouldn't get to.
The Tickerday app is almost here — watchlists, daily check-ins, weather-change alerts, and an Almanac that keeps score of every call. We'll watch the market while you sleep, so you never fly blind again.
Free to download the day it lands — the web desk is open now